A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LEQ506 given orally on a daily dosing schedule in patients with advanced solid tumors.
Advanced Solid Tumors|Recurrent or Refractory Medulloblastoma|Locally Advanced or Metastatic Basal Cell Carcinoma
DRUG: LEQ506
To determine the maximum tolerated dose and characterize the dose limiting toxicities of LEQ506, 21 day cycles
To characterize the safety and tolerability of LEQ506 treatment, 21 day cycles|To characterize the pharmacokinetics of LEQ506, 21 day cycles|To characterize the pharmacodynamic effects of LEQ506 in skin and tumor samples, 21 day cycles|Tumor response, every 6 weeks
This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LEQ506 given orally on a daily dosing schedule in patients with advanced solid tumors.